LOXO-260

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Carcinoma, Non-Small-Cell LungThyroid Neoplasms

Phase 1

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

CompletedNCT05241834

Eli Lilly and CompanyCarcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

Start: 2022-03-23End: 2026-06-03Updated: 2026-08-21

Unknown Phase

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Eli Lilly and CompanyCarcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

Updated: 2024-02-28

Related Papers

A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).

Journal of Clinical Oncology2022-06-0115 citations